Radiopharm Theranostics Limited (RADX)

NASDAQ: RADX · Real-Time Price · USD

Compare

5.14

-0.01 (-0.19%)

At close: Jan 16, 2026, 4:00 PM EST

5.14

0.00 (0.03%)

After-hours: Jan 16, 2026, 7:32 PM EST

Radiopharm Theranostics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Operating Revenue	3.63	0.3	0.29	-	-
Other Revenue	8.88	1.66	5.92	-	-
Revenue	12.51	1.96	6.21	-	-
Revenue Growth (YoY)	538.86%	-68.46%	-	-	-
Cost of Revenue	31.11	21.61	19.53	7.49	-
Gross Profit	-18.6	-19.65	-13.32	-7.49	-
Selling, General & Admin	14.64	13.04	12.23	7.64	0.3
Operating Expenses	16.53	15.68	15.27	12.44	1.16
Operating Income	-35.13	-35.33	-28.59	-19.93	-1.16
Interest Expense	-0.07	-0.64	-0.09	-9.35	-
Interest & Investment Income	0.89	0.05	0.15	0.01	-
Currency Exchange Gain (Loss)	0.14	0.09	-0.26	-1.11	-0
EBT Excluding Unusual Items	-34.17	-35.83	-28.79	-30.38	-1.16
Gain (Loss) on Sale of Assets	-	-1.69	-	-	-
Asset Writedown	-	-1.48	-3.1	-	-
Other Unusual Items	-4.07	-8.86	-2.68	-	-
Pretax Income	-38.24	-47.85	-34.57	-30.38	-1.16
Income Tax Expense	0.1	0.1	0.04	0.04	-
Net Income	-38.34	-47.95	-34.61	-30.42	-1.16
Net Income to Common	-38.34	-47.95	-34.61	-30.42	-1.16
Shares Outstanding (Basic)	2,081	386	306	181	-
Shares Outstanding (Diluted)	2,081	386	306	181	-
Shares Change (YoY)	438.49%	26.36%	68.74%	-	-
EPS (Basic)	-0.02	-0.12	-0.11	-0.17	-
EPS (Diluted)	-0.02	-0.12	-0.11	-0.17	-
Free Cash Flow	-36.65	-22.98	-23.25	-9.91	-0.08
Free Cash Flow Per Share	-0.02	-0.06	-0.08	-0.06	-
Gross Margin	-148.63%	-	-214.52%	-	-
Operating Margin	-280.77%	-1803.82%	-460.41%	-	-
Profit Margin	-306.44%	-2448.23%	-557.36%	-	-
Free Cash Flow Margin	-292.88%	-1173.12%	-374.36%	-	-
EBITDA	-32.53	-32.2	-25.29	-16.94	-
EBITDA Margin	-260.03%	-	-	-	-
D&A For EBITDA	2.6	3.13	3.3	2.98	-
EBIT	-35.13	-35.33	-28.59	-19.93	-1.16
EBIT Margin	-280.77%	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q